Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.65 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112168 | 0.93 | HTT (0.60) | HTTLMNAKMT2AALDH1A1TSHR | |
| SCHEMBL12505792 | 0.92 | HTT (0.80) | HTTLMNAKMT2AALDH1A1TSHR | |
| SCHEMBL30823638 | 0.90 | HTT (0.84) | HTTLMNAKMT2AALDH1A1TSHR | |
| SCHEMBL22289415 | 0.90 | HTT (0.84) | HTTLMNAKMT2AALDH1A1TSHR | |
| SCHEMBL14082491 | 0.89 | ALDH1A1 (0.77) | HTTLMNAKMT2AALDH1A1TSHR | |
| SCHEMBL3093230 | 0.85 | ALDH1A1 (0.65) | HTTLMNAKMT2AALDH1A1TSHR | |
| SCHEMBL14082169 | 0.85 | HTT (0.71) | HTTLMNAKMT2AALDH1A1TSHR | |
| SCHEMBL2406255 | 0.84 | HTT (1.00) | HTTLMNAKMT2AALDH1A1TSHR | |
| SCHEMBL5436807 | 0.84 | HTT (1.00) | HTTLMNAKMT2AALDH1A1TSHR | |
| SCHEMBL3101304 | 0.83 | ALDH1A1 (0.67) | HTTKMT2AALDH1A1TSHRTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105386-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE DEUTSCHLAND (DE) | 2015-04-16 | — | — | US | disclosed |
| US-8895749-B2 | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators | ABBVIE INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130310378-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8445686-B2 | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators | ABBVIE INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100273828-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310378-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | GABRR3, ROCK1, ROCK2 | HTT 4433/4885LMNA 2453/4885KMT2A 3138/4885 |
| US-20150105386-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | GABRR3, ROCK1, ROCK2 | HTT 4425/4885LMNA 2482/4885KMT2A 3124/4885 |
| US-20100273828-A1 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS | GABRR3, ROCK1, ROCK2 | HTT 4433/4885LMNA 2453/4885KMT2A 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.